Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  NovoCure Limited    NVCR   JE00BYSS4X48

NOVOCURE LIMITED

(NVCR)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Novocure : to Report Third Quarter 2020 Financial Results

10/02/2020 | 08:57am EST

Novocure (NASDAQ: NVCR) announced today that it will report financial results for the third quarter 2020 on Thursday, October 29, 2020, before the U.S. financial markets open. Novocure’s management will host a conference call and webcast to discuss its financial results for the three and nine months ended September 30, 2020, at 8 a.m. EDT on Thursday, October 29, 2020. Analysts and investors can participate in the conference call by dialing 855-442-6895 for domestic callers and 509-960-9037 for international callers, using the conference ID 5453859.

The webcast and earnings slides presented during the webcast can be accessed live from the Investor Relations page of Novocure’s website, www.novocure.com/investor-relations, and will be available for at least 14 days following the call. Novocure has used, and intends to continue to use, its investor relations website, as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

About Novocure

Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure’s commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma and in the U.S. for the treatment of adult patients with malignant pleural mesothelioma. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer, gastric cancer and glioblastoma.

Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New Hampshire, Malvern, Pennsylvania and New York City. Additionally, the company has offices in Germany, Switzerland, Japan and Israel. For additional information about the company, please visit www.novocure.com or follow us at www.twitter.com/novocure.

Forward-Looking Statements

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, clinical trial progress, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, coverage, collections from third-party payers and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other words and terms of similar meaning. Novocure’s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions as well as issues arising from the COVID-19 pandemic and other more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on February 27, 2020 and its Quarterly Report on Form 10-Q filed on April 30, 2020 with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Novocure does not intend to update publicly any forward-looking statement, except as required by law. Any forward-looking statements herein speak only as of the date hereof. The Private Securities Litigation Reform Act of 1995 permits this discussion.


© Business Wire 2020
All news about NOVOCURE LIMITED
01/12NOVOCURE : Wedbush Adjusts NovoCure's Price Target to $159 From $110, Maintains ..
MT
01/11NOVOCURE : Earnings Flash (NVCR) NOVOCURE Posts Q4 Revenue $144M
MT
01/11NOVOCURE : Announces Fourth Quarter and Full Year 2020 Preliminary Net Revenues ..
BU
2020NOVOCURE : to Participate in the 39th Annual J.P. Morgan Virtual Healthcare Conf..
BU
2020INSIDER TRENDS : NovoCure Insider Sale Slowing 90-Day Buy Trend
MT
2020NOVOCURE : Announces National Reimbursement in Switzerland for Optune® in Combin..
BU
2020NovoCure Starts Enrollment in Phase 3 Trial of Optune as Glioblastoma Combina..
MT
2020NOVOCURE : First Patient Enrolled in Novocure's Global Phase 3 TRIDENT Trial of ..
BU
2020NOVOCURE : to Participate in the Evercore ISI 2020 Virtual HealthCONx Conference
BU
2020NOVOCURE : Announces 43 Presentations on Tumor Treating Fields at Society for Ne..
BU
More news
Financials (USD)
Sales 2020 493 M - -
Net income 2020 25,3 M - -
Net cash 2020 160 M - -
P/E ratio 2020 712x
Yield 2020 -
Capitalization 17 214 M 17 214 M -
EV / Sales 2020 34,6x
EV / Sales 2021 29,1x
Nbr of Employees 782
Free-Float 85,2%
Chart NOVOCURE LIMITED
Duration : Period :
NovoCure Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVOCURE LIMITED
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 9
Average target price 137,75 $
Last Close Price 169,10 $
Spread / Highest target 18,3%
Spread / Average Target -18,5%
Spread / Lowest Target -48,0%
EPS Revisions
Managers and Directors
NameTitle
Asaf Danziger Chief Executive Officer & Director
William F. Doyle Executive Chairman
Wilhelmus Groenhuysen Chief Operating Officer
Ashley Cordova Chief Financial Officer, SVP-Investor Relations
Uri Weinberg Chief Science Officer
Sector and Competitors
1st jan.Capitalization (M$)
NOVOCURE LIMITED-2.28%17 214
MASIMO CORPORATION-1.75%14 517
PENUMBRA, INC.39.45%8 861
ASAHI INTECC CO., LTD.-7.57%8 741
GETINGE AB2.58%6 474
JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD.8.22%4 722